Literature DB >> 33603157

Restoring IL-2 to its cancer immunotherapy glory.

Asher Mullard.   

Abstract

Entities:  

Year:  2021        PMID： 33603157     DOI： 10.1038/d41573-021-00034-6

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  15 in total

Review 1.  Resilient T-cell responses in patients with advanced cancers.

Authors:  Joanina K Gicobi; Emilia R Dellacecca; Haidong Dong
Journal:  Int J Hematol       Date:  2022-07-21       Impact factor: 2.319

2.  Systematic discovery and perturbation of regulatory genes in human T cells reveals the architecture of immune networks.

Authors:  Jacob W Freimer; Oren Shaked; Sahin Naqvi; Nasa Sinnott-Armstrong; Arwa Kathiria; Christian M Garrido; Amy F Chen; Jessica T Cortez; William J Greenleaf; Jonathan K Pritchard; Alexander Marson
Journal:  Nat Genet       Date:  2022-07-11       Impact factor: 41.307

Review 3.  Roles of natural killer cells in immunity to cancer, and applications to immunotherapy.

Authors:  Natalie K Wolf; Djem U Kissiov; David H Raulet
Journal:  Nat Rev Immunol       Date:  2022-05-30       Impact factor: 108.555

4.  Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors.

Authors:  Natalie K Wolf; Cristina Blaj; Lora K Picton; Gail Snyder; Li Zhang; Christopher J Nicolai; Chudi O Ndubaku; Sarah M McWhirter; K Christopher Garcia; David H Raulet
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-19       Impact factor: 12.779

5.  Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas.

Authors:  Cüneyt Sönmez; Johannes Wölfer; Markus Holling; Benjamin Brokinkel; Walter Stummer; Heinz Wiendl; Christian Thomas; Andreas Schulte-Mecklenbeck; Oliver M Grauer
Journal:  Sci Rep       Date:  2022-04-26       Impact factor: 4.996

6.  Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy.

Authors:  Jin-Qing Liu; Chengxiang Zhang; Xinfu Zhang; Jingyue Yan; Chunxi Zeng; Fatemeh Talebian; Kimberly Lynch; Weiyu Zhao; Xucheng Hou; Shi Du; Diana D Kang; Binbin Deng; David W McComb; Xue-Feng Bai; Yizhou Dong
Journal:  J Control Release       Date:  2022-03-14       Impact factor: 11.467

7.  Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma.

Authors:  Maryam Pourmaleki; Caitlin J Jones; Charlotte E Ariyan; Zheng Zeng; Mono Pirun; Daniel A Navarrete; Yanyun Li; Mianlei Zhang; Subhiksha Nandakumar; Carl Campos; Saad Nadeem; David S Klimstra; Claire F Temple-Oberle; Thomas Brenn; Evan J Lipson; Kara M Schenk; Julie E Stein; Janis M Taube; Michael G White; Raymond Traweek; Jennifer A Wargo; John M Kirkwood; Billel Gasmi; Stephanie L Goff; Alex D Corwin; Elizabeth McDonough; Fiona Ginty; Margaret K Callahan; Andrea Schietinger; Nicholas D Socci; Ingo K Mellinghoff; Travis J Hollmann
Journal:  Cancer Immunol Res       Date:  2022-03-01       Impact factor: 12.020

Review 8.  Interleukin 2-Based Fusion Proteins for the Treatment of Cancer.

Authors:  Alana MacDonald; T-C Wu; Chien-Fu Hung
Journal:  J Immunol Res       Date:  2021-11-08       Impact factor: 4.818

9.  Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy.

Authors:  Dongyao Wang; Binqing Fu; Xiaokun Shen; Chuang Guo; Yanyan Liu; Junfei Zhang; Rui Sun; Ying Ye; Jiabin Li; Zhigang Tian; Haiming Wei
Journal:  Signal Transduct Target Ther       Date:  2021-11-05

10.  A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells.

Authors:  Erin A Holcomb; Weiping Zou
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 19.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.